Navigation Links
Obesity and Diabetes Are Increasing in Cats
Date:11/10/2010

ST. JOSEPH, Mo., Nov. 10, 2010 /PRNewswire/ -- Diabetes isn’t just a human disease. This November – American Diabetes Month® – pet owners should know that the feline members of their families could suffer from the condition, too.

Type 2 diabetes is the most common form in the United States and occurs in both cats and people. Feline diabetes, a treatable and manageable disease on the rise, affects approximately one in 200 cats nationwide.

"Similar to humans, obesity predisposes cats to diabetes, making diet a major factor in maintaining a cat’s health," says Ruth MacPete, DVM, a San Diego based veterinarian. "Feline diabetes, like most diseases, is easier to treat the earlier it is diagnosed."

Early warning signs include:

  • Increased thirst
  • Sudden increase in appetite
  • Sudden weight loss (despite an increase in appetite)
  • Increased urination
  • Increased lethargy

Most cats with feline diabetes may still maintain an active and healthy lifestyle. Along with appropriate diet and exercise, veterinarians often recommend insulin injections.

"Veterinarians are fortunate enough to now have PROZINC® insulin, the first and only FDA approved long-acting insulin for cats, available to help them effectively regulate their feline diabetic patients,” says MacPete. As with all insulins, cats should be evaluated for pre-existing conditions and currently prescribed medications prior to treatment with PROZINC. Routine monitoring of clinical signs and blood parameters, such as glucose and fructosamine, is essential to maintain a regulated cat.

While November is American Diabetes Month®, pet owners should monitor their cats for symptoms of feline diabetes year-round. The American Association of Feline Practitioners recommends that a veterinarian examine cats at least once a year and twice annually if they are over the age of seven.

For more information about feline diabetes, please visit www.MyCatHasDiabetes.com.

For more information about PROZINC, please visit www.prozinc.us.

About Boehringer Ingelheim

Boehringer Ingelheim Vetmedica, Inc. (St. Joseph, Mo.), is a subsidiary of Boehringer Ingelheim Corporation based in Ridgefield, Conn., and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 138 affiliates in 47 countries and approximately 41,300 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2008, Boehringer Ingelheim posted net sales of US $17 billion (11.6 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development. For more information, please visit: www.bi-vetmedica.com.


'/>"/>
SOURCE Boehringer Ingelheim Vetmedica, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. American Council on Exercise (ACE) Announces Nationwide Effort to Eliminate Obesity in America
2. Results of Two New Clinical Studies Show Promise of Emerging Mobile Health Technology to Combat Obesity Epidemic
3. A Majority of Surveyed PCPs and Endocrinologists Indicate that they will Prescribe Contrave, Lorqess and Qnexa if these Therapies are Approved for Obesity
4. Abbott Laboratories Agrees to Withdraw Its Obesity Drug Meridia
5. Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010
6. SIRIUS XMs Doctor Radios The Deans List To Focus On Link Between Early Antibiotic Use In Children And Obesity
7. FierceBiotech Names Obesity Company Gelesis to Fierce 15 List of Top Emerging Biotech Companies
8. Obesity Expert to Speak to FDA in Support of Treatment Options for Obese Patients
9. Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
10. Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity From Its Broad Metabolic Disease Franchise at ADA Scientific Sessions
11. Zydus Novel Orally Administered GLP-1 Agonist - ZYOG1 to treat Diabetes and Obesity Enters Phase I Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Consumers have taken ... regulators/payers have placed more emphasis on patient outcomes. ... support programs in the pharmaceutical industry have evolved ... Consequently, pharmaceutical companies are focusing on becoming more ... providing products and services that improve health. ...
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... , June 24, 2016 ... has announced the addition of the " Global ... This report ... provides an updated review, including its applications in various ... total market, which includes three main industries: pharmaceutical and ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... Nevada (PRWEB) , ... June 24, 2016 , ... ... Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations ... in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a ...
Breaking Medicine News(10 mins):